The headline number from KEYNOTE-B15 (also called EV-304) is already public: Merck reports that Keytruda plus Padcev cut the risk of event-free survival events by 47% and the risk of death by 35% in cisplatin-eligible patients with muscle-invasive bladder cancer. What readers searching for the ESMO 2026 health-related quality of life (HRQoL) readout want to know is a different question: did patients feel worse for it? On October 24, 2026, that answer is not in the public record we reviewed.
Trend tracking attributes the HRQoL story to Oncodaily, and the topic is climbing in search. Yet the records available to us identify KEYNOTE-B15 only as a Phase 3 study. They do not confirm an ESMO 2026 session focused on HRQoL, an abstract number, a presenter, or a single patient-reported score. This article reports what is documented, flags what is not, and explains why the missing piece matters. If you track how AI money is flowing into biotech, this trial shows what a drug has to prove before any model-designed molecule reaches a bladder cancer clinic.
Don't miss new tech stories on Google
Add Tech Insider once in the Google app and our stories appear in your news suggestions.
KEYNOTE-B15 at ESMO 2026: What Is Confirmed and What Is Not
Start with the verified part. KEYNOTE-B15/EV-304 is an open-label, randomized Phase 3 trial registered as NCT04700124. It tests perioperative enfortumab vedotin (Padcev) plus pembrolizumab (Keytruda) against neoadjuvant gemcitabine plus cisplatin, each followed by surgery, in patients with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin-based chemotherapy. The Mount Sinai clinical trial listing describes the same comparison.
Now the unverified part. We found no HRQoL instrument, no score, no time point, and no statistical result tied to this trial. We also found no ESMO 2026 presentation date, no abstract number, and no on-record speaker quote. The quote-gathering tools we ran for this story returned zero verifiable quotes, so none appear here. When you see a social post quoting specific HRQoL percentages from an ESMO session, treat it as unconfirmed until it links to an abstract.
| Item | Status on October 24, 2026 | Source basis |
|---|---|---|
| Trial name and identifier (KEYNOTE-B15/EV-304, NCT04700124) | Confirmed | Trial listings, Merck |
| Event-free survival, overall survival, pCR results | Confirmed | Published results, Merck |
| Grade 3 or higher adverse event rates | Confirmed | Published results |
| HRQoL instrument, scores, time points | Unconfirmed | None found |
| ESMO 2026 session date and abstract number | Unconfirmed | None found |
| Presenter and speaker quote | Unconfirmed | None found |
The 47% Event-Risk Cut: Event-Free Survival Results
Event-free survival (EFS) was the efficacy headline. At two years, the published results show 79.4% of patients on enfortumab vedotin plus pembrolizumab remained event-free, against 66.2% on cisplatin plus gemcitabine. The hazard ratio came in at 0.53 with a 95% confidence interval of 0.41 to 0.70 and P below 0.001. The PubMed record carries those figures, and Merck’s headline translates the 0.53 into a 47% lower risk of an EFS event.
A 13.2-point absolute gap at two years is large for perioperative bladder cancer, where a cystectomy is itself a major operation and recurrence is the fear that shapes every treatment decision. The confidence interval is also tight. Its upper bound of 0.70 still implies a 30% relative reduction in risk, so even the pessimistic end of the estimate clears the bar most oncologists would call clinically meaningful.
Overall Survival: 86.9% Versus 81.3% at Two Years
Overall survival (OS) is harder to move than EFS, and the trial moved it. At two years, 86.9% of patients on the antibody-drug conjugate combination were alive, compared with 81.3% on chemotherapy. The hazard ratio for death was 0.65, with a 95% confidence interval of 0.48 to 0.89 and a two-sided P of 0.006. Merck rounds that 0.65 into a 35% lower risk of death.
The absolute OS gap is 5.6 percentage points. That is smaller than the EFS gap, which is normal at this follow-up because deaths accumulate more slowly than recurrences. Still, an OS benefit with a confidence interval that excludes 1.0 matters for regulators and payers. It lets the sponsors argue the regimen extends life and does not merely delay relapse.
Pathological Complete Response: 55.8% Versus 32.5%
Pathological complete response (pCR) means surgeons and pathologists find no remaining cancer in the removed bladder tissue. The published results put pCR at 55.8% with enfortumab vedotin plus pembrolizumab and 32.5% with cisplatin plus gemcitabine. That is a 23.3-point difference, and it explains the downstream survival gains. Patients who reach pCR tend to do well, so a regimen that wipes out tumors in more than half of cases changes the odds for the whole group.
For clinicians, pCR also changes the surgical conversation. A bladder with no residual cancer reassures the surgeon and the patient. It is also where HRQoL research gets interesting, because a patient who reaches pCR may recover differently than one who needs further treatment.
| Endpoint (published results) | EV plus pembrolizumab | Cisplatin plus gemcitabine | Hazard ratio / P |
|---|---|---|---|
| 2-year event-free survival | 79.4% | 66.2% | 0.53 (0.41-0.70), P<0.001 |
| 2-year overall survival | 86.9% | 81.3% | 0.65 (0.48-0.89), P=0.006 |
| Pathological complete response | 55.8% | 32.5% | Not reported in fact sheet |
| Grade 3 or higher adverse events | 75.7% | 67.2% | Not reported in fact sheet |
| Patients enrolled | 808 in total across both arms | ||
Safety: 75.7% Versus 67.2% Grade 3 or Higher Events
Efficacy is half of the ledger. The published safety data show grade 3 or higher adverse events in 75.7% of patients on the new combination and 67.2% on chemotherapy. That 8.5-point gap is real but modest, and it sits beside a 47% cut in event risk. Most oncologists will read that trade as favorable.
The raw rate does not tell you what those events feel like day to day. Two regimens can produce similar grade 3 counts and very different lived experiences. One may bring fatigue and nausea that fade after a cycle, the other may leave symptoms that linger into recovery. That distinction is exactly what HRQoL measurement exists to capture, and it is why the missing HRQoL readout is not a footnote.
Why HRQoL Data Decide the Real-World Case
Health-related quality of life captures what patients report about physical function, symptoms, emotional state, and daily life. In a perioperative trial, it answers practical questions. Do patients get through four neoadjuvant cycles without losing the strength needed for surgery? Do they recover afterward? Do they stay on the adjuvant phase, or quit early because they feel unwell?
Regulators, guideline panels, and insurers increasingly ask for these answers alongside survival. A treatment that wins on EFS but leaves patients markedly worse off for months faces a harder sell than one that holds quality of life steady. By contrast, if HRQoL held up in KEYNOTE-B15, sponsors gain a second argument and clinicians gain reassurance when they counsel patients who fear the toxicity of a newer drug.
We cannot say which way the data point. No instrument, score, or time point is documented in the records we reviewed, so any claim that quality of life came out better or worse would be invention. What we can say is that the question is legitimate, the trial design makes it answerable, and a formal presentation would let readers judge it.
Trial Design: 808 Patients and a Perioperative Sandwich
The trial enrolled 808 patients. Reported protocol details describe the experimental arm in two phases around surgery, and the structure matters because HRQoL could shift differently in each.
Neoadjuvant phase: four 21-day cycles
Patients in the experimental arm received four 21-day cycles of pembrolizumab plus enfortumab vedotin before surgery. That is roughly twelve weeks of treatment ahead of the operation, and it is the window in which fatigue, skin reactions, or neuropathy could affect fitness for cystectomy. Patients in the comparator arm received neoadjuvant gemcitabine plus cisplatin.
Adjuvant phase: 13 plus 5 cycles
After surgery, the reported protocol included 13 cycles of adjuvant pembrolizumab and five cycles of adjuvant enfortumab vedotin. Long maintenance phases are where HRQoL gaps often widen, since patients are recovering from a major operation while still receiving drugs. A longitudinal HRQoL analysis would need to track both phases to give an honest picture.
| Design element | Detail |
|---|---|
| Registry identifier | NCT04700124 |
| Phase and format | Phase 3, open-label, randomized |
| Population | Cisplatin-eligible muscle-invasive bladder cancer |
| Experimental arm | Pembrolizumab plus enfortumab vedotin, perioperative |
| Comparator arm | Neoadjuvant gemcitabine plus cisplatin, then surgery |
| Neoadjuvant schedule | Four 21-day cycles, then surgery |
| Adjuvant schedule | 13 cycles pembrolizumab plus five cycles enfortumab vedotin |
| Enrollment | 808 patients |
One caution applies to open-label designs. Patients and doctors know which arm they are in, and patient-reported outcomes can drift when people know they received the newer or older drug. Good HRQoL analysis plans account for that, and any presentation worth trusting will discuss it.
Where Hardware and Wearables Meet Patient-Reported Outcomes
This story is filed under hardware because the way HRQoL gets measured is changing, and devices are driving it. Trials have traditionally collected patient-reported outcomes on paper or clinic tablets. Sponsors now increasingly pair questionnaires with phone apps and wearables that log activity and sleep between visits. We found nothing in our records saying KEYNOTE-B15 used any device-based capture, so treat this section as industry context and not a claim about the trial.
The consumer side is moving fast. Sleep-tracking form factors such as the Alloop Trio cube, band, and ring show how small sensors can run overnight without friction. Chip makers are targeting the same niche, as our coverage of the Synaptics Astra SR200 wearable chips explains. A cystectomy patient wearing a low-power sensor could give researchers objective activity data to set beside a questionnaire score.
Device data raises a privacy bill, though. Health records are already a favorite target, a point driven home when the Quest Diagnostics breach hit a single system. Any sponsor that streams symptom and activity data from patients’ wrists needs a security plan that matches the sensitivity. More coverage of the gear itself sits in our hardware section.
Market Impact for Merck, Pfizer, and Astellas
Three companies appear in the records: Merck, Pfizer, and Astellas. Merck markets Keytruda, while Pfizer and Astellas share the Padcev franchise. Pfizer’s own announcement says the U.S. FDA granted priority review to a supplemental application for Padcev plus Keytruda as perioperative treatment for muscle-invasive bladder cancer regardless of cisplatin eligibility.
We do not have stock moves, revenue forecasts, or peak-sales estimates for this combination in our verified sources, so we will not guess. The strategic logic is simple, though. Moving a regimen from metastatic disease into the perioperative setting reaches patients earlier, who stay on therapy for a defined period and whose cure rates matter most. Every extra patient treated at the curative stage is worth more to payers and to the sponsors than one treated after relapse.
HRQoL data feeds directly into that commercial case. Health-technology assessors in Europe and elsewhere weigh patient experience when they decide whether a price is justified. A clean quality-of-life story would strengthen reimbursement dossiers. A messy one would hand payers a negotiating lever.
Historical Context: From Chemotherapy Doublets to Antibody-Drug Conjugates
For many years, cisplatin-based chemotherapy before cystectomy has been the reference approach for cisplatin-eligible MIBC, which is why KEYNOTE-B15 uses gemcitabine plus cisplatin as its comparator. Chemotherapy helps some patients and leaves many with residual disease at surgery. The 32.5% pCR rate on the comparator arm shows how much room for improvement existed.
The new approach pairs a checkpoint inhibitor with an antibody-drug conjugate, a drug that delivers a cell-killing payload to tumor cells carrying a target protein. Enfortumab vedotin targets that kind of protein, and pembrolizumab releases the immune system’s brakes. Putting both before and after surgery stretches the treatment window across the highest-risk months. That design philosophy mirrors a wider shift in oncology, where earlier-line use of targeted agents is replacing older cytotoxic standards.
Biotech investors are watching the same trend from the discovery side. Our piece on the UK’s AI biosecurity lab shows how governments are putting public money behind AI-assisted life science. Whether those efforts yield a bladder cancer drug is a long-horizon bet, but the trial bar they must clear is the one KEYNOTE-B15 now sets.
Competitive Comparison: What Each Arm Offers Patients
Compare the two approaches on the facts we hold. The experimental arm wins on every efficacy metric the published results report: EFS, OS, and pCR. It loses on one: higher grade 3 or higher adverse events at 75.7% versus 67.2%. It also asks more of patients in time commitment, with 13 cycles of adjuvant pembrolizumab and five of adjuvant enfortumab vedotin after surgery.
The chemotherapy arm remains the known quantity. Oncologists have decades of experience managing its side effects, and it is cheaper to deliver. Its disadvantage is plain in the numbers, with 66.2% EFS at two years against 79.4%. For a patient weighing a harder-hitting regimen against a familiar one, the HRQoL data would be the tiebreaker, and today that tiebreaker is missing.
Information quality is a third axis. Patients routinely research treatments with AI chatbots and wearables, and the quality of that advice varies. Our look at shadow AI use among workers hints at how widely people turn to unsanctioned tools. Clinicians should expect patients to arrive with half-remembered claims about KEYNOTE-B15, which is one more reason for sponsors to publish plain-language summaries.
Predictions: What to Watch After KEYNOTE-B15
These are analyst judgments, not reported facts. Treat them as informed expectations that could change as data arrives.
- An HRQoL abstract will surface. A trial this large, with this much commercial weight, almost always yields patient-reported outcome analyses. Expect one at a major oncology meeting or in a journal, even if it is not the ESMO 2026 session that trend tracking suggests.
- Quality of life will look broadly comparable, not dramatically better. Given the higher grade 3 or higher event rate, a clear HRQoL win for the new combination would surprise us. A finding of no clinically meaningful deterioration is the more likely framing.
- Regulators will lean on survival first. With a 0.65 hazard ratio for death, the OS result carries the filing. HRQoL will shape labeling language and payer talks more than approval itself.
- Sponsors will push for longer follow-up. Two-year numbers are strong, but clinicians want to know whether the gap holds at three and five years.
- Digital capture will grow. Future perioperative trials will lean harder on app-based questionnaires and wearable sensors, which is where the hardware angle becomes commercial.
How to Verify a Claim About This Trial
Because the HRQoL story is moving faster than its paperwork, readers need a checking routine. First, look for an abstract number or a DOI. A real presentation has one, and a rumor does not. Second, confirm the instrument name and the time points, since a bare claim that quality of life improved means nothing without them. Third, check whether the figures are from the randomized comparison or from a subgroup.
Fourth, confirm the source. Company press releases from Merck, Pfizer, and Astellas are reliable for what they state, but they are also marketing documents. Peer-reviewed records on PubMed and the registry entry for NCT04700124 are better anchors. When a claim cites none of these, hold it at arm’s length.
FAQ: KEYNOTE-B15 and the ESMO 2026 HRQoL Question
What is KEYNOTE-B15? KEYNOTE-B15, also called EV-304 and registered as NCT04700124, is an open-label, randomized Phase 3 trial. It compares perioperative enfortumab vedotin plus pembrolizumab with neoadjuvant gemcitabine plus cisplatin in cisplatin-eligible muscle-invasive bladder cancer.
Was an HRQoL analysis presented at ESMO 2026? The records we reviewed do not confirm it. They identify the study as Phase 3 but give no ESMO 2026 session, abstract number, or presenter for an HRQoL readout. Trend tracking attributes the story to Oncodaily, so check the official ESMO program for the final listing.
How much did the combination improve event-free survival? At two years, event-free survival was 79.4% with enfortumab vedotin plus pembrolizumab and 66.2% with cisplatin plus gemcitabine. The hazard ratio was 0.53 (95% CI 0.41 to 0.70, P below 0.001), which Merck summarizes as a 47% lower risk of an EFS event.
Did patients live longer? Two-year overall survival was 86.9% versus 81.3%, with a hazard ratio for death of 0.65 (95% CI 0.48 to 0.89, two-sided P=0.006). Merck describes that as a 35% lower risk of death.
What were the safety findings? Grade 3 or higher adverse events occurred in 75.7% of patients on the new combination and 67.2% on chemotherapy. Pathological complete response was 55.8% versus 32.5%.
How many patients were in the trial? Reported enrollment was 808 patients. The experimental arm received four 21-day neoadjuvant cycles, surgery, then 13 adjuvant cycles of pembrolizumab and five of enfortumab vedotin.
Which companies are involved? The records name Merck, Pfizer, and Astellas. Pfizer has announced FDA priority review of a supplemental application for Padcev plus Keytruda in perioperative muscle-invasive bladder cancer regardless of cisplatin eligibility.
Where can I read the primary data? Start with the PubMed record for the published results, the Mount Sinai trial listing for design details, and the Merck and Pfizer press pages for the sponsors’ summaries.
